New startup ideas · Health and bio · Healthcare and bio
startup idea
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
- Software subscription
- Enterprise
- $100B+ market
- Collapses a cost 10x
- Global from day one
5/5
venture judge
8
similar startups, last 2 years (14 all-time)
97%
of 4 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$1,800 · 6 weeks · 20 prospects
For under $1,800 and six weeks, prove that HTS lab directors will export multi-vendor run data and pay $2,500 up front for a hand-built failure-prediction audit before any product exists.
1Focus group: who and where
Director of High-Throughput Screening or Head of Lab Operations at a US biotech or pharma site with 40+ instruments from at least three vendors, whose reagent and consumables waste is already a named line in this year's budget review
where to find 20 · LinkedIn Sales Navigator filtered on titles 'Director, High Throughput Screening', 'Head of Lab Operations', 'Lab Automation Lead' at US companies with 200-5,000 employees; the SLAS (Society for Laboratory Automation and Screening) member directory and its LinkedIn group; readers of Lab Manager; warm intros from field application scientists in your own networks
2Sell first, build later
A retrospective failure audit of 90 days of run logs across up to 10 instruments, delivered as a written report within 3 weeks of data receipt, naming the share of failed runs that were predictable and the top three parameter changes, with the fee credited to year one of a per-instrument subscription
the ask · $2,500 per audit, invoiced 100% up front; follow-on subscription quoted at $150 per instrument per month
a real yes · A real yes is a paid $2,500 invoice plus delivered data exports, or a signed pilot order with a start date. Not a yes: 'send us more information', an unpaid audit, an enthusiastic call with no NDA signed, or a vendor intro without a named customer
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Failure cost worksheet calls
$300 · 14 days
Book 15 thirty-minute calls using Sales Navigator InMail and SLAS connections. Walk each prospect through a one-page worksheet: runs per month, failure rate, reagent cost per failed run, who notices first. The founder runs every call and asks for last month's actual failed-run count, not an estimate.
keep going if · 10 of 15 name a tracked annual waste figure above $250,000 and can state last month's failed-run count within the call
2. Vendor channel probe
$0 · 14 days
Run 5 calls with field application scientist managers or service directors at instrument vendors and CROs the prospects named on the worksheet calls. Pitch a co-branded failure audit for one shared customer and ask what data ports they would open or block. This directly tests the stated risk that vendors lock the telemetry.
keep going if · 2 of 5 agree in writing to introduce one customer for a joint audit; 0 of 5 say the telemetry is contractually theirs
3. Data export fake door
$100 · 21 days
At the end of each worksheet call, ask the lab to export 90 days of run logs from instruments of at least two vendors under a two-page mutual NDA you send the same day. No product is mentioned; the artifact is the NDA plus a one-page export instruction sheet per vendor. Willingness to actually pull the data is the test of both pain and vendor lock.
keep going if · 5 of 15 labs deliver usable exports covering 2+ vendors within 10 days of the call
4. Paid concierge failure audit
$500 · 21 days
For labs that exported data, hand-analyze the logs with scripts and spreadsheets, then deliver a report listing which failed runs showed a detectable signature before reagents were consumed and what parameter change would have caught them. Sell it as a $2,500 retrospective audit, invoiced before the work starts and credited against a future subscription.
keep going if · 3 of 5 labs that exported data pay the $2,500 invoice before delivery
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$2,500
per prospect, refundable
how · A paid design-partner audit invoiced up front through Stripe Invoicing, signed by the lab director or procurement against a one-page statement of work; where procurement cannot pay inside 30 days, collect instead a signed SOW with a dated data-delivery commitment and a purchase order in review set up: Stripe Invoicing ↗
what it reserves · One of five audit slots in the first cohort, the credited subscription price of $150 per instrument per month locked for year one, and priority on their vendors' integrations
refund · Refunded in full if the report is not delivered within 3 weeks of complete data receipt
target · 3 paid audits from 15 worksheet calls within 42 days
Go: build it if
3 audits paid at $2,500, 5 labs delivered multi-vendor exports, and at least 40% of failed runs in the audited data show a predictable signature
Kill: stop if
Fewer than 3 of 15 labs will export data under NDA, or 0 audits paid after 5 export deliveries, or 3 of 5 vendor calls assert contractual ownership of the telemetry
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
88
Idea Score, 0-100 · raw 53.4 x 1.64
Active
competition: more crowded than 65% of ideas · headwind x0.67
+2.9
government priorities, secondary (19 matching grants)
Trend
73
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)100
- Rounds announced 2025+ in the sector68
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
62
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain100
- Founders' yes-rate in decks18
100x potential
93
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge100
- Market size axis100
- Moat axis100
- Neighbours still alive81
- Technologist judge75
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were predicts, lab, fail, reagents, connects, instrument, fleet, pharma.
The idea in full
- What
- Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them. It is a per-instrument subscription installed by field application scientists and resold through instrument vendors and CRO partners. Customers see the same experimental output for roughly a tenth of the wasted runs and consumables.
- Why now
- Lavo Life Sciences died in 2023 selling AI for drug formulation as a discovery bet, while capital in this cluster now flows to execution layers, Ambrosia Biosciences at $100.0M Series B on 2026-03-31 and AbInitio Bio (yc X26) on manufacturing intelligence; the failed framing was discovery, the surviving framing is cost per successful run.
- Wedge: first customer and entry point
- One high-throughput screening group with 40-plus instruments from three vendors, where reagent waste is already a tracked budget line, entered through a single vendor's field service organization.
- Path to 100x
- Global spend on research instruments, reagents and the labor around failed runs is well over $100B a year, and a tenth of it is recoverable by the layer that sits across vendors. Failure prediction improves with every additional instrument-year in the federated corpus, so the first network to cross a few thousand connected instruments is measurably more accurate than any later entrant and becomes the default clause in vendor service contracts.
- Ceiling
- If failure modes turn out to be mostly site-specific rather than transferable, the cross-customer model stops compounding and this becomes a per-lab analytics tool.
- Closest real companies, as the generator saw them
- Atlas Discovery and Strand AI predict biology; Harbor rebuilds trial operations; AbInitio Bio focuses on manufacturing. Assaygrid ignores the science question entirely and sells the unit cost of a successful experiment, which is why it can be vendor-neutral and sold through channels.
- Main risk
- Instrument vendors decide the telemetry is theirs and lock the data ports rather than reselling.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
5/5
Vendor-neutral telemetry across a $100B+ instrument and reagent spend compounds per instrument-year, and channel resale through vendors scales without founder hours.
Bootstrapper
3/5
Per-instrument subscription against an already-tracked reagent waste budget is real money, but field-scientist installs and vendor channel deals push revenue out years.
Operator
5/5
Reagent waste is already a tracked budget line in the screening group, and vendor field service organizations carry the sale into the existing workflow.
Technologist
4/5
Failure prediction improves with every instrument-year across vendors, so crossing a few thousand connected instruments is an accuracy lead no later entrant can buy.
Risk
2/5
Both the data and the channel run through instrument vendors, who can close telemetry ports and end the business in one decision.
trends
2/5
The discovery-to-execution reframing after Lavo's 2023 death is a narrative, not a shift; cross-vendor failure prediction was equally possible years ago.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (predicts, lab, fail, reagents, connects, instrument, fleet, pharma): 14 all-time, 8 from the last two years. Same matching as Idea Check.
MovieBall is an AI-native production OS helping for studios and creators — accelerating the content pipeline and turning gut-feel intuition into data-driven decisions.
The vendor-neutral coordination and translation layer for biomanufacturing data, connecting pharma sponsors and their manufacturing partners so AI can finally scale and deliver real value.
Where drug teams run their entire program, discovery to FDA approval
The Intelligence layer for Drug Manufacturing
The Fastest Multimodal Inference OS
Adaptive data transfer optimization for high-performance infrastructure, Berkeley CS founders.
The data layer for scientific research
Elnora is an AI co-pilot for biomedical lab protocols that learns from every experiment to accelerate drug discovery.
India's fastest medicine delivery in just 30 minutes
AIoT monitoring, workflow, and evidence systems for regulated labs.
Lab automation robots for life-science workflows.
Automata is a global biotech company providing robotic automation solutions to the life sciences industry.
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1127
startup-relevant grants in Healthcare and bio
$590M
awarded in the sector, tracked
130
opportunities open now in the sector
- In vitro myelination assay modeling the environment of MS lesions for predictive discovery of remyelinating therapiesawardhigh relevance
NIH / NINDS · SBIR phase II · $1M · posted 2026-08-06
- SBIR Phase I: Physics-Informed Control and Optimization of Thermochemical Reactor Arraysawardhigh relevance
National Science Foundation · SBIR Phase I · $305K · posted 2026-07-06
- Point of care diagnostic to improve access to gynecological screening in low-resource settingsawardhigh relevance
NIH / NCI · STTR phase I · $400K · posted 2025-09-01
- A Universal Platform for Ultrahigh-Throughput Biocatalyst Evolution With micro-Mass Spectrometryawardhigh relevance
NIH / NIGMS · SBIR phase II · $307K · posted 2025-08-01
- MUSICO: An in silico platform for evaluating the effects of disease and drug effectiveness in HCM and DCM cardiomyopathiesawardhigh relevance
NIH / NHLBI · SBIR phase I · $298K · posted 2025-07-15
- CAREER: Vehicle adaptive shared control: Predicting human driver cognitive and intent states for personalized control decisions by automated vehiclesawardmedium relevance
National Science Foundation · HCC-Human-Centered Computing · $613K · posted 2026-07-11
- Artificial Intelligence-Assisted Socially Interactive Agents to Transform Undergraduate STEM Advisingawardmedium relevance
National Science Foundation · IUSE · $400K · posted 2026-08-20
- Collaborative Research: Anticipatory Robotics: World Models and Generative Planning for Safe, Human-Aligned Autonomyawardmedium relevance
National Science Foundation · FRR-Foundationl Rsrch Robotics · $402K · posted 2026-08-07
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 130 → 118 → 216 → 173 → 71 new companies 2022 → 2026 · 92% aliveYC S26: 14 in this cluster, 6% of the batch (was 4% in X26) (F26 is still forming: 21 listed)Since February, of 444 YC companies here: 4 acquired, 5 shut down, 37 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- Software subscription
- Path to 100x
- Collapses a cost 10x
- Market size
- $100B+ market
- Capital intensity
- Capital-medium (ops, field teams)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Deep tech: ML, hardware, bio
- Go-to-market
- Partners and channels
- Moat
- Network effects
- Geography
- Global from day one
- Regulation
- Unregulated
- Vibe
- Boring business
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Health and bio · Healthcare and bio
Claimsmith
The agent platform where healthcare's back office gets rebuilt by everyone but us.
Claimsmith is a no-code platform where hospitals, billing companies, and health IT vendors build and run AI agents for administrative work: eligibility checks, prior authorization, claims appeals, and records chasing.
Fictional company written 2026-08-22 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.